Evaluation of the comparative efficacy of selamectin against flea (Ctenocephalides felis felis) infestations on dogs and cats in simulated home environments.
The comparative efficacy of monthly administration of selamectin or lufenuron against Ctenocephalides felis felis on dogs and cats was evaluated over a 5-month period in flea-infested environments. Twenty-four dogs and 32 cats were randomly allocated to receiving a topical treatment with selamectin or an oral administration of tablets containing lufenuron/milbemycin oxime (for dogs) or lufenuron only (for cats). Each product was administered in accordance with the manufacturer's label recommendations. Eight dogs and four cats served as untreated sentinels. Treatments were administered on days 0, 30, 60, 90, and 120. Each animal received an application of 100 fleas on days -28 and -21, and then weekly applications of 20 fleas from days 91 through 147. Flea comb counts were performed on day -6, and every 2 weeks after day 0. From day 29 (dogs) or day 44 (cats) to day 150, geometric mean flea counts for selamectin were < or =0.4. Mean flea counts for animals assigned to treatment with selamectin were significantly lower (P=0.0001) than for animals assigned to treatment with lufenuron at all assessments after day 0.
Ritzhaupt
L K
LK
Veterinary Medicine Clinical Development, Pfizer Global Research and Development, Pfizer Inc., Eastern Point Road, Mailstop 8200-40, Groton, CT 06340, USA. larry_k_ritzhaupt@groton.pfizer.com
Rowan
T G
TG
Jones
R L
RL
Cracknell
V C
VC
Murphy
M G
MG
Shanks
D J
DJ
D000818:Animals; D000977:Antiparasitic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004334:Drug Administration Schedule; D004478:Ectoparasitic Infestations / Q000188:drug therapy / Q000662:veterinary*; D005260:Female; D006799:Housing, Animal; D007306:Insecticides / Q000494:pharmacology / Q000627:therapeutic use; D007559:Ivermectin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D005423:Siphonaptera / Q000187:drug effects*; D016896:Treatment Outcome; D005466:Fluorocarbons
D000977:Antiparasitic Agents; D001549:Benzamides; D007306:Insecticides; D007559:Ivermectin; C070364:fluphenacur; D005466:Fluorocarbons; C414354:selamectin